Mitochondrial-derived peptide researched for metabolic regulation, exercise mimicry, insulin sensitivity, and longevity.
Last Updated: May 2026
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene, identified in 2015 as the first member of the mitochondrial-derived peptide (MDP) family. Research interest focuses on metabolic regulation, insulin sensitivity, exercise mimicry, and potential longevity applications. MOTS-c is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories.
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by the mitochondrial genome, identified in 2015 as the first member of the mitochondrial-derived peptide family and proposed to regulate metabolic homeostasis through AMPK activation, GLUT4 translocation, and direct mitochondrial-to-nuclear signaling. The peptide is endogenously expressed but with declining serum levels in older adults — preclinical work suggests exogenous supplementation may compensate for age-related decline. Evidence level: Preclinical (rodent metabolism, exercise capacity, insulin sensitivity); limited human pharmacokinetic data.
In preclinical rodent studies, MOTS-c administration improved glucose tolerance, reduced age-related insulin resistance, enhanced exercise capacity, and extended healthspan in some models. Human clinical data is sparse — no published Phase 2 or Phase 3 trials in any indication as of May 2026. A small number of Phase 1 pharmacokinetic studies have been conducted; the mechanism translates plausibly from rodent to human but efficacy translation has not been clinically established. Evidence level: Preclinical (multiple rodent studies, in vitro mechanism). Human translation: not yet established at Phase 2/3 scale.
MOTS-c is not a weight-loss peptide in the same category as GLP-1 agonists — it does not produce the appetite suppression or large-magnitude weight loss seen with semaglutide, tirzepatide, or retatrutide. MOTS-c is researched for metabolic health markers (insulin sensitivity, mitochondrial function, exercise tolerance) rather than direct weight reduction. Comparing MOTS-c to GLP-1 compounds on weight loss is a category error.
| Compound | Mechanism | Primary research focus | Evidence stage |
|---|---|---|---|
| Retatrutide | GLP-1 + GIP + glucagon | Weight loss, diabetes | Phase 3 |
| Semaglutide | GLP-1 (single) | Weight loss, diabetes | FDA-approved |
| MOTS-c | Mitochondrial-derived, AMPK | Insulin sensitivity, exercise mimicry, longevity | Preclinical / Phase 1 |
Human safety data for MOTS-c is limited. In available Phase 1 pharmacokinetic studies and community-reported research use, side effects have been mild and infrequent — typically injection-site reactions and occasional gastrointestinal effects. Preclinical rodent studies have not surfaced significant toxicity signals at researched doses. Long-term safety in humans is unknown. Evidence level: Preclinical safety, limited Phase 1; long-term human safety unestablished.
MOTS-c is not approved for any medical indication anywhere in the world as of May 2026. It is sold strictly as a research-use-only compound by third-party laboratories. No clinical trial program for MOTS-c is currently advancing toward an NDA. Buyers should treat MOTS-c as an early-stage research peptide with strong preclinical signals but unestablished human efficacy. Regulatory context in are peptides legal.
MOTS-c synthesis is mature enough that production quality across vendors is generally good, but the small molecular size (16 amino acids) and limited demand mean fewer labs have optimized large-batch production — creating variance in purity and identity confirmation across vendors. Independent HPLC purity testing and mass spectrometry identity confirmation are the meaningful purity signals. Guidance in our how-to-test-peptides hub.
Peptigrity purchases MOTS-c vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above this section shows the cross-shop dataset. Tests come from labs including Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.
MOTS-c is researched for metabolic health markers — insulin sensitivity, mitochondrial function, exercise capacity — not primarily for weight loss. It is not in the same therapeutic category as GLP-1 receptor agonists. Users seeking direct weight-loss compounds should reference semaglutide, tirzepatide, or retatrutide.
MOTS-c is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.
Human evidence for MOTS-c is limited to small Phase 1 pharmacokinetic studies and community-reported research use. No Phase 2 or Phase 3 efficacy trials have been published in any indication as of May 2026. The preclinical signal in rodents is strong but human translation has not been clinically established at scale.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay. Peptigrity publishes independent MOTS-c test results from ISO-accredited labs in the table above. COA interpretation in red flags in peptide certificates of analysis.
No. MOTS-c is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in preclinical studies has varied widely; translation to a human research protocol is medical practice. Anyone considering investigational compound use should consult a licensed physician.
The longevity hypothesis for MOTS-c rests on preclinical rodent data showing healthspan extension in some models and the observation that endogenous MOTS-c serum levels decline with age in humans. The hypothesis is mechanistically plausible but unestablished clinically. Treat longevity claims for MOTS-c with the appropriate skepticism — the evidence stage is preclinical, not human RCT.
This section is for educational and informational purposes only and does not constitute medical advice. MOTS-c is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.